MediGene AG is a public quoted German biotechnology company with subsidiaries in UK (Avidex) and US (MediGene, Inc.). The company was founded in 1994 as a spin off from Munich Gene Center. MediGene’s technologies include EndoTAG®, HSV oncolytic viruses and mTCRs. The company focuses on cancer and autoimmune diseases and is the first German biotech with a drug on the market – Eligard® for prostate cancer. The products of the company include Polyphenon® E, Oracea®, EndoTAG®-1 etc.